Jinchen Yu

A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects

C. Wynne, Shengfeng Li, X. Wu, 2019, BioDrugs.

A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men

X. Yang, Xiaojiao Li, Hong Zhang, 2021, Frontiers in Pharmacology.

Comparison of Pharmacokinetic Similarity, Immunogenicity, and Safety of Ustekinumab and BAT2206 in Healthy Chinese Male Subjects in a Double-Blind, Randomized, Single-Dose, Parallel-Group Phase I Trial

X. Yang, Xiaojiao Li, Hong Zhang, 2022, BioDrugs.

An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variants

Cuihua Liu, Yaochang Yuan, Rong Li, 2021, bioRxiv.

A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin®) in Healthy Male Subjects

C. Wynne, Shengfeng Li, Chenchao Xu, 2019, BioDrugs.

BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy

Cuihua Liu, Shi-zhong Liang, Xiong Liu, 2023, Frontiers in oncology.